Johnson & Johnson halts mid-stage trial of experimental eczema drug
I'm PortAI, I can summarize articles.
Dec 26 (Reuters) - Johnson & Johnson ( JNJ ) said on Friday it has discontinued a mid-stage study of its experimental drug to treat patients with moderate to severe atopic dermatitis, after it failed to meet efficacy goals in an interim analysis. (Reporting by Siddhi Mahatole in Bengaluru; Editing by Shilpi Majumdar)
Source: fidelity The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments